This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, K. C. Articles by Ross, B. D. Search for Related Content PubMed PubMed Citation Articles by Lee, K. C. Articles by Ross, B. D.

Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy

Authors' Affiliations: Departments of ¹ Radiology, ² Radiation Oncology, ³ Biostatistics, ⁴ Internal Medicine, and ⁵ Center for Molecular Imaging, University of Michigan Medical School, Biomedical Sciences Research Building, Ann Arbor, Michigan

Requests for reprints: Brian D. Ross, Center for Molecular Imaging, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200. Phone: 734-763-2099; Fax: 734-763-5447; E-mail: bdross{at}umich.edu.

Purpose: The American Cancer Society estimates that in 2006, 212,920 women will be diagnosed with breast cancer and that 40,970 women will die from the disease. The development of more efficacious chemotherapies has improved outcomes, but the rapid assessment of clinical benefit from these agents remains challenging. In breast cancer patients receiving neoadjuvant chemotherapy, treatment response is traditionally assessed by physical examination and volumetric-based measurements, which are subjective and require macroscopic changes in tumor morphology. In this study, we evaluate the feasibility of using diffusion magnetic resonance imaging (MRI) as a reliable and quantitative measure for the early assessment of response in a breast cancer model.

Experimental Design: Mice implanted with human breast cancer (MX-1) were treated with cyclophosphamide and evaluated using diffusion MRI and growth kinetics. Histologic analyses using terminal nucleotidyl transferase–mediated nick end labeling and H&E were done on tumor samples for correlation with imaging results.

Results: Cyclophosphamide treatment resulted in a significant reduction in tumor volumes compared with controls. The mean apparent diffusion change for treated tumors at days 4 and 7 posttreatment was 44 ± 5% and 94 ± 7%, respectively, which was statistically greater (P < 0.05) than the control tumors at the same time intervals. The median time-to-progression for control and treated groups was 11 and 32 days, respectively (P < 0.05).

Conclusion: Diffusion MRI was shown to detect early changes in the tumor microenvironment, which correlated with standard measures of tumor response as well as overall outcome. Moreover, these findings show the feasibility of using diffusion MRI for assessing treatment response of a breast tumor model in a neoadjuvant setting.

This article has been cited by other articles:

				H.-M. Baek, J.-H. Chen, K. Nie, H. J. Yu, S. Bahri, R. S. Mehta, O. Nalcioglu, and M.-Y. Su Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative 1H MR Spectroscopy Radiology, June 1, 2009; 251(3): 653 - 662. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]

				S. Kim, L. Loevner, H. Quon, E. Sherman, G. Weinstein, A. Kilger, and H. Poptani Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck Clin. Cancer Res., February 1, 2009; 15(3): 986 - 994. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394. [Abstract] [Full Text] [PDF]

				J. Lazovic, M. C. Jensen, E. Ferkassian, B. Aguilar, A. Raubitschek, and R. E. Jacobs Imaging Immune Response In vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme Clin. Cancer Res., June 15, 2008; 14(12): 3832 - 3839. [Abstract] [Full Text] [PDF]

				K. C. Lee, S. Sud, C. R. Meyer, B. A. Moffat, T. L. Chenevert, A. Rehemtulla, K. J. Pienta, and B. D. Ross An Imaging Biomarker of Early Treatment Response in Prostate Cancer that Has Metastasized to the Bone Cancer Res., April 15, 2007; 67(8): 3524 - 3528. [Abstract] [Full Text] [PDF]